TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.~* Subject must complete the treatment and follow-up period, or have been discontinued for rising intact parathyroid hormone (iPTH), from an AMG 416 phase 3 parent study prior to the start of dosing in this study: 20120229 (NCT01785849), 20120230 (NCT01788046), or 20120359 (NCT01932970).~* Subject agrees to not participate in another study of an investigational agent during the study.~* Other Inclusion Criteria may apply~Exclusion Criteria:~* Currently receiving treatment in another investigational device or drug study.~* Currently receiving other investigational procedures while participating in this study.~* Subject has known sensitivity to any of the products or components to be administered during dosing.~* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.~Other Exclusion Criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Etelcalcetide (Type: EXPERIMENTAL): Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM- V) criteria for moderate to severe Alcohol Use Disorder (AUD),~* Must produce positive urine toxicology screens on admission to study~* Must demonstrate good health as verified by screening examination~* Must be able to read English and complete study evaluations~* Must be able to provide informed written and verbal consent~Exclusion Criteria:~* Meeting current use disorder for any other psychoactive substance, excluding nicotine.~* Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication~* EKG evidence at baseline screening of any clinically significant conduction abnormalities including a Bazlett's QTc (corrected QT interval) of \>470 msec.~* Must not be on monophasic contraceptives, nursing or pregnant.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Guanfacine XR 3mgs/daily (Type: EXPERIMENTAL): * Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)
- Placebo (for guanfacine) (Type: PLACEBO_COMPARATOR): * Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The study population will consist of eighty subjects who are 18 years or older and have a biopsy-proven lentigo maligna.~* The subjects must have a LM that is in a location amenable to treatment with imiquimod, express a willingness and ability to comply with study requirements, and tolerate an outpatient surgical procedure.~* All participants will sign consent documents prior to enrollment.~* The typical age of patient that develops a LM is beyond the child-bearing range.~Exclusion Criteria:~* In the event that a patient with a LM is pregnant, they will be excluded from the study.~* inability to tolerate the surgical procedure~* invasive melanoma~* previous surgery on the site of interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site.
- 2 (Type: EXPERIMENTAL): Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with type 2 diabetes 18 to 85 years Metformin monotherapy \> 4 weeks HbA1c 6.5 - 9.5%~Exclusion Criteria:~FPG \> 270 mg/dl Use of other antidiabetic drugs than metformin major cardiovascular event in the last 6 months (MI, stroke...)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Experimental
- Sitagliptin (Type: ACTIVE_COMPARATOR): Active comparator (drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to randomization.~2. On IV epoetin alfa or beta maintenance therapy continuously prescribed for a minimum of 8 weeks prior to randomization.~3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the Screening Period.~Exclusion Criteria~1. Females who are pregnant or breast-feeding.~2. Known intolerance to any erythropoiesis stimulating agent or pegylated molecule or to all parenteral iron supplementation products.~3. Known bleeding or coagulation disorder.~4. Known hematologic disease or cause of anemia other than renal disease~5. Poorly controlled hypertension.~6. Evidence of active malignancy within one year prior to randomization.~7. Temporary (untunneled) dialysis access catheter.~8. A scheduled kidney transplant.~9. A scheduled surgery that may be expected to lead to significant blood loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): None
- Epoetin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting plasma Glucose- 126-270~* HbA1c \<10%~* Hematocrit \>34%~* Serum creatinine \<1.8mg/dl~* AST (aspartate aminotransferase) \< 2 times upper limit of normal~* ALT (Alanine aminotransferase) \< 2 time upper limit of normal~* Alkaline phosphatase \<2 times upper limit of normal~Exclusion Criteria:~* Type 1 DM~* Fasting plasma glucose \>270 mg/dl~* Thiazolidinedione therapy~* Insulin therapy in last 3 months~* Congestive heart failure \> NYHA (New York Heart Association) class II~* History of dyspnoea on exertion~* Abnormal breath sounds~* EKG changes other than non-specific ST-T changes in the ECG (Electro-CardioGram) or LVH (Left Ventricular Hypertrophy)~* H/O Claudication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
- Pioglitazone (Type: ACTIVE_COMPARATOR): One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept (Enbrel®) in Psoriasis - Pediatrics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Patients with plaque psoriasis~* Patient may not receive certain psoriasis medications during the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48).
- Etanercept (Type: EXPERIMENTAL): Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with capacity admitted to hospital within 24 hrs either a single acute POD or more than one dose of paracetamol (staggered) and deemed to require treatment with NAC.~2. Provision of written informed consent~3. Males and females of at least 16 years of age~Exclusion Criteria:~1. Patients that do not have the capacity to consent to participate in the study~2. Patients detained under the Mental Health Act or deemed unfit by the Investigator to participate due to mental health.~3. Patients with known permanent cognitive impairment~4. Patients who are pregnant or nursing~5. Patients who have previously participated in the study~6. Unreliable history of POD~7. Patients presenting after 24hrs of POD~8. Patients who take anticoagulants (e.g. warfarin) therapeutically or have taken an overdose of anticoagulants~9. Patients who, in the opinion of the responsible clinician/nurse, are unlikely to complete the full course of NAC e.g. expressing wish to self-discharge~10. Prisoners~11. Non-English speaking patients. (Study information material will only be produced in English in view of the known and stable demographic of the Edinburgh self-harm population).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetylcysteine (N-acetylcysteine; NAC) (Type: NO_INTERVENTION): NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
- PP100-01 (Calmangafodipir)+ NAC (Type: EXPERIMENTAL): In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~* Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~* Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~* Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose vs. Standard Influenza Vaccine in Adult SOT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Organ transplant recipient on at least one immunosuppressive~* Age \>=18~* Outpatient status~* Greater than 3 months post transplant~Exclusion Criteria:~* Has already received influenza vaccination for 2016-2017 season~* Egg allergy or allergy to previous influenza vaccine~* Febrile illness in the past one week~* Active Cytomegalovirus viremia~* Use of Rituximab in the past 6 months~* Ongoing or recent (in past 30 days) therapy for acute rejection~* Chronic kidney insufficiency (creatinine clearance ≤30mL/min or dialysis-dependent~* Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome)~* Receipt of intravenous immunoglobulin (IVIG) in the past 30 days or planning to receive IVIG in the next 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluzone High-dose Influenza Vaccine (Type: EXPERIMENTAL): This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
- Standard 2016-2017 Flu vaccine (Type: ACTIVE_COMPARATOR): This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Participants with solid tumors or lymphoproliferative disease~* Participants receiving chemotherapy~* Participants for whom erythropoietin is indicated for pre-study Hb level and observed anemic symptoms: Hb less than (\<) 11 g/dL or 6.83 millimoles per liter (mmol/L)~* ECOG performance status of 0, 1, or 2~Exclusion Criteria:~* Resistant hypertension~* Acute chronic bleeding within 3 months prior to study~* Iron deficiency that is unmanageable prior to study~* Hypersensitivity to the active substance or any of the excipients of the product~* Pregnant or breastfeeding women~* Epoetin treatment within 6 months prior to study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NeoRecormon in Symptomatic Anemia (Type: None): Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline For Smokers In Recovery From Alcohol Dependence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant female cigarette smoker; 18-years-of-age or older and reporting smoking at least an average of 10 cigarettes per day for the past year.~2. A history of alcohol dependence based on DSM IV criteria as assessed by the Alcohol Dependence Scale and the physician investigator~3. A minimum of 6 months of abstinence from alcohol use as assessed by the physician investigator~4. Subject must be able to complete all the study visits~5. Subject must be in general good health as determined by medical history, physical exam and physician investigator~6. Subject must provide written informed consent to participate in the study.~Exclusion Criteria:~1. Current treatment with another investigational drug.~2. Current use (within past 30 days) of nicotine replacement therapy, bupropion, rimonabant, varenicline, nortriptyline, clonidine, or other medications known to be effective for treating tobacco dependence.~3. Subject has current (past 30 days) major depressive disorder or has a history of another psychiatric disorder such as psychosis or bipolar disorder.~4. Current (past 6 months) drug abuse corroborated by the Drug Abuse Screening Test (DAST-20) and physician interview.~5. Regular use of other tobacco products (i.e. pipe, cigar, smokeless tobacco) within the past 30 days.~6. Females who are pregnant, lactating or likely to become pregnant during the trial and not willing to use an acceptable form of contraception during the medication phase. For women of child-bearing potential, a pregnancy test will be performed prior to entry into the study and at the end of the medication phase.~7. A history of a major cardio-vascular event in the past 3 months including unstable angina, acute MI or coronary angioplasty.~8. Known allergy to varenicline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Varenicline (Type: OTHER): Everyone on study will receive Varenicline daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Either A or B below and who were not adequately controlled with their lipid-modifying therapy:~A) Participants with heterozygous familial hypercholesterolemia (heFH) with or without established coronary heart disease (CHD) or CHD risk equivalents~OR~B) Participants with hypercholesterolemia together with established CHD or CHD risk equivalents.~Exclusion criteria:~* Age \< 18 years~* LDL-C \<70 mg/dL (\< 1.81 mmol/L)~* Fasting serum triglycerides \> 400 mg/dL (\>4.52 mmol/L)~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
- Alirocumab (Type: EXPERIMENTAL): Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete